Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1164 results about "Nervous system" patented technology

The nervous system is a highly complex part of an animal that coordinates its actions and sensory information by transmitting signals to and from different parts of its body. The nervous system detects environmental changes that impact the body, then works in tandem with the endocrine system to respond to such events. Nervous tissue first arose in wormlike organisms about 550 to 600 million years ago. In vertebrates it consists of two main parts, the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS consists of the brain and spinal cord. The PNS consists mainly of nerves, which are enclosed bundles of the long fibers or axons, that connect the CNS to every other part of the body. Nerves that transmit signals from the brain are called motor or efferent nerves, while those nerves that transmit information from the body to the CNS are called sensory or afferent. Spinal nerves serve both functions and are called mixed nerves. The PNS is divided into three separate subsystems, the somatic, autonomic, and enteric nervous systems. Somatic nerves mediate voluntary movement. The autonomic nervous system is further subdivided into the sympathetic and the parasympathetic nervous systems. The sympathetic nervous system is activated in cases of emergencies to mobilize energy, while the parasympathetic nervous system is activated when organisms are in a relaxed state. The enteric nervous system functions to control the gastrointestinal system. Both autonomic and enteric nervous systems function involuntarily. Nerves that exit from the cranium are called cranial nerves while those exiting from the spinal cord are called spinal nerves.

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Neurophysiological magnetic stimulation system

A neurophysiological magnetic stimulation (NMS) method includes obtaining motor thresholds over one or both motor strips adhered to the patient's head or the equivalent anatomic region for treatment of non-brain, nervous system disorders. The method further includes applying magnetic stimulation coils to a therapeutic target region of the patient's brain, brainstem, spinal cord, or peripheral nervous system and applying NMS in increasing amplitudes as tolerated over the course of treatment.
Owner:BIED ADAM +1

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Novel association of active ingredients, pharmaceutical and / or nutraceutical compositions containing it and their use in the prevention and repair of damage to the central and peripheral nervous system

PCT designated stage expiredWO2025146608A1Nervous disorderAntipyreticNervous systemNutrition
The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of i) an extract of Gastrodia elata and ii) at least one ingredient selected from the group comprising or, alternatively, consisting of citicoline, L-acetylcarnitine and, preferably, at least one vitamin of group D, and / or mixtures thereof, and / or at least one vitamin of group B, and / or mixtures thereof. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices (Regulation (EU) 2017 / 745) and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the nervous system and in the prevention and / or treatment of central and peripheral neuropathies.
Owner:FUTURA S R L SOVICO

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Method and system for evaluating and training attention of children

The invention relates to a child attention evaluation and training method and system, and the method comprises the steps: obtaining a brain wave mode, an eyeball movement track, an emotion activation level and autonomic nervous system function data of a child in real time, and generating multi-dimensional biological signal data; based on the multi-dimensional biological signal data, generating evaluation task data; generating dynamic task parameters according to biological signal data and behavior performance data in the evaluation task data; generating an attention feedback signal based on the dynamic task parameters; according to the attention feedback signal, a training task integrating work memory, suppression control and cognitive flexibility is constructed, and cognitive function training data is generated; and based on the cognitive function training data, synchronously sharing the attention performance data of the children to the parent terminal and the teacher terminal, generating life situation intervention suggestions, and iteratively optimizing evaluation parameters according to a long-term effect evaluation result. Therefore, the accuracy of children attention evaluation and training can be improved.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Advantageous benzofuran compositions for mental disorders or enhancement

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
Owner:TACTOGEN INC

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Methods and devices for photobiomodulation

Systems and methods are described for treatment of neurological conditions in which transcranial illumination using infrared, near-infrared and / or red wavelengths of light are delivered into the brain of a patient using a portable head wearable device. Systems and methods are also described to deliver light to patient tissues for photobiomodulation, particularly through the patient's mouth.
Owner:JELIKALITE LLC

Targeted treatment of spliceopathy-induced neurological disorders

Disclosed are methods of treating a subject with a neurological disease associated with a splicing defect caused by TDP-43 proteinopathies, comprising administering to said subject an agent to increase expression levels and / or stability of hnRNP L, thereby attenuating and / or repairing the splicing defect. The disclosure also relates to nucleic acids targeting heterogeneous nuclear ribonucleoprotein L (hnRNP L), and their use.
Owner:AUTTX LLC

Devices and methods for application of a magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Epilepsy early warning method and system based on electroencephalogram signals

The invention discloses an epilepsy early warning system based on electroencephalogram signals, and relates to the technical field of nervous systems, the epilepsy early warning system comprises an information acquisition module, a data division module, a data preprocessing module, a model training module and a real-time reasoning module, the information acquisition module is used for determining a few-channel electroencephalogram signal acquisition position and acquiring electroencephalogram signal data; the data division module is used for recording the total number of times of epileptic seizure events and defining the interval of seizure, the early stage of seizure and the period of seizure for each epileptic seizure event, and the data preprocessing module is used for data denoising and dynamically adjusting the overlapping proportion of a data window by adopting a sliding window-based adaptive overlapping data slicing method so as to obtain the data of the epileptic seizure event. The model training module is used for completing a preprocessing process to relieve the problem of data imbalance, and is used for constructing and training an early warning model based on a deep learning model of time-frequency feature fusion; the complexity and wearing burden of the equipment are effectively reduced, and efficient epilepsy early warning is realized.
Owner:JINGXINWEIER (CHANGZHOU) ELECTRONIC TECHNOLOGY CO LTD

Sleep-aiding and nerve-soothing oral liquid and preparation process thereof

The invention belongs to the technical field of sleep-aiding oral liquids, and discloses a sleep-aiding nerve-calming oral liquid and a preparation process thereof, the oral liquid is composed of the following components: a plant fermentation broth, fructo-oligosaccharide, gamma-aminobutyric acid, casein hydrolysis peptide, a saussurea involucrata culture, and pyrroloquinoline quinone disodium salt; wherein the plant fermentation liquor is prepared from spina date seeds, poria cocos, lilies, Chinese dates, lotus seeds, lophatherum gracile, seville orange flowers, red roses with double petals, roselle, wheat, licorice roots, peach kernels, sweet-scented osmanthus and plant lactobacillus BXM2. The core component spina date seed saponin A is combined with gamma-aminobutyric acid to directly regulate the GABAergic nervous system, shorten the sleep latency and effectively help sleep and tranquilize the nerves; casein hydrolysis peptide promotes secretion of melatonin, and cooperates with the saussurea involucrata culture to resist oxidative stress, improve the sleep structure and restore circadian rhythm; small molecular active peptides and flavonoid glycosides are generated through fermentation, and anxiety mood, fatigue state and qi and blood circulation are improved; nano embedding and targeted delivery technologies are adopted in the whole process, the bioavailability is high, and the risk of drug dependence is avoided.
Owner:HANYI VALLEY (HAINAN) HEALTH TECHNOLOGY GROUP CO LTD

Device and method to selectively and reversibly modulate a nervous system structure to inhibit pain

The present disclosure is directed to a system and method for selectively and reversibly modulating targeted neural and non-neural tissue of a nervous system for the treatment of pain. An electrical stimulation is delivered to the treatment site that selectively and reversibly modulates the targeted neural- and non-neural tissue of the nervous structure, inhibiting pain while preserving other sensory and motor function, and proprioception.
Owner:AVENT INVESTMENT LLC

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Mental state real-time monitoring system based on intelligent wearable device

The invention relates to the technical field of mental state monitoring, in particular to a mental state real-time monitoring system based on intelligent wearable equipment, which comprises a physiological signal analysis module, a voice data analysis module, a mental fluctuation evaluation module, a fatigue boundary judgment module and a mental state analysis module. According to the method, by extracting key physiological and voice signal features, the activity stability of the neural signal and the autonomic nervous system of an individual can be more accurately judged, the stability of the physiological signal is effectively evaluated, and by calculating the fluctuation trend of the mental state and combining physiological and voice data, the accuracy of the physiological signal is improved. Real-time changes of emotion fluctuation and mental load of an individual can be captured more comprehensively, so that mental state monitoring is more comprehensive and accurate, real-time evaluation of mental fatigue is performed according to physiological and voice signal changes, a more objective fatigue judgment basis is provided, the accuracy of mental health state evaluation is enhanced, and the mental health state evaluation efficiency is improved. And more accurate mental health state information is provided for individuals.
Owner:BEIJING FENGTAI DISTRICT MENTAL HEALTH CENT (BEIJING FENGTAI DISTRICT MENTAL HEALTH PREVENTION & TREATMENT HOSPITAL)

Use of a nutritional composition for non-therapeutic purposes of improving brain development and promoting neural and / or cognitive development

The present invention relates to the use of a nutritional composition for non-therapeutic purposes of improving brain development, promoting neural and / or cognitive development. The nutritional composition comprises medium and long-chain fatty acid triglycerides and human milk oligosaccharides, and the mass ratio of the medium and long-chain fatty acid triglycerides to the human milk oligosaccharides is 1:1 to 9:1. In this composition, the medium and long-chain fatty acid triglycerides and the human milk oligosaccharides have a synergistic effect in terms of the said use, significantly improving the effect of the composition in improving brain development, promoting neural and / or cognitive development. This composition can be used for preventing or improving brain developmental retardation, nervous system and / or cognitive developmental retardation; at the same time, it can also be used for preventing or improving impaired learning ability, impaired mental behavior, impaired memory or reduced attention span, etc., and has good application prospects.
Owner:INNER MONGOLIA MENGNIU DAIRY IND (GROUP) CO LTD +1

Cardiovascular data monitoring method for cardiovascular medicine department

The invention relates to the field of biosensors, and discloses a cardiovascular data monitoring method for the cardiovascular medicine department. According to the method, electrocardio, respiration and blood oxygen signals are synchronously collected through a non-invasive terminal, sleep apnea events are analyzed and recognized in a combined mode, the electrocardio signals are deeply analyzed to detect cardiovascular abnormalities, and time sequence characterization of the function state of the autonomic nervous system is generated based on heart rate variability; and further constructing a time sequence causal reasoning model, quantifying the triggering effect of the respiratory event on the cardiovascular event, generating a comprehensive night cardiovascular risk layering index, and triggering graded early warning. According to the invention, non-sensitive, long-time-history and high-precision night cardiovascular risk dynamic assessment and causal mechanism analysis are realized.
Owner:ANKANG PEOPLES HOSPITAL

Neuromodulation / neurostimulation system for mitigating locomotor deficits of parkinson's disease, spinal cord injury (SCI), stroke and / or other neurological disorders

A combined neuromodulation and / or neurostimulation system for mitigating locomotor deficits of / or neuronal disorders, especially Parkinson's disease, said system comprises: at least one Deep Brain Stimulation System for providing Deep Brain Stimulation to brain tissue of a subject, at least one control unit, configured and adapted to provide stimulation data, at least one stimulation unit, operatively connected to the at least one control unit, the at least one stimulation unit being configured and adapted to deliver epidural electrical stimulation to the dorsal side of the spinal cord of said subject, and at least one implantable pulse generator, wherein the at least one stimulation unit includes one or more electrodes configured to be implanted epidurally, the one or more electrodes being operatively connected to the at least one IPG.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Reversing aging of the central nervous system

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Application of compound for inhibiting phosphorylation of ARMC10 in preparation of medicine for antagonizing tin-induced nervous system injury

ActiveCN121606581AOrganic active ingredientsNervous disorderNervous systemMitochondrial Dynamic
The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.
Owner:ARMY MEDICAL UNIV

Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.
Owner:DEUT ZENT FUER NEURODEGENERATIVE ERKRANKUNGEN EV +1

Devices and methods for application of magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Devices and methods for application of a magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Cyclic peptides for treatment of central nervous system injury and uses thereof

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.
Owner:BIOCELLS BEIJING BIOTECH CO LTD

Antifungal composition comprising natamycin and at least one insecticide

The invention relates to a composition comprising natamycin and at least one insecticide that interferes with the nervous system and / or muscular system of insects and nematodes. The invention further relates to methods employing natamycin and at least one insecticide that interferes with the nervous system and / or muscular system of insects and nematodes, preferably said composition, for protecting a plant or plant part, for improving the development and / or yield of an agricultural plant, and for protecting a soil and / or a growth substrate.
Owner:CERADIS PATENT BV

program

To provide a program that allows a measurement object person to easily check his or her state in detail using a smartphone or the like by various expressions.SOLUTION: A moving image acquisition unit 111 acquires moving image data showing a moving image that a user has taken of his or her face by a camera 16. The acquired moving image data is accumulated in a moving image DB 121 of a memory 12. A pulse measuring unit 112 reads out the moving image data from the moving image DB 121, and measures vital values including a pulse on the basis of the moving image data. A ratio calculation unit 113 calculates a ratio of a sympathetic nerve to a parasympathetic nerve on the basis of the pulse included in the measured vital values. An activity calculation unit 114 calculates the activity of the entire autonomous nerve on the basis of the pulse included in the measured vital values. A plotting part 115 plots a state of the user's nervous system indicated by LF / HF and TP on a plane with the LF / HF and the TP as two axes.SELECTED DRAWING: Figure 10
Owner:SENSING CO LTD